Attacking the supply wagons to starve cancer cells to death
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The constitutive anabolism of cancer cells not only supports proliferation but also addicts tumor cells to a steady influx of exogenous nutrients. Limiting access to metabolic substrates could be an effective and selective means to block cancer growth. In this review, we define the pathways by which cancer cells acquire the raw materials for anabolism, highlight the actionable proteins in each pathway, and discuss the status of therapeutic interventions that disrupt nutrient acquisition. Critical open questions to be answered before apical metabolic inhibitors can be successfully and safely deployed in the clinic are also outlined. In summary, recent studies provide strong support that substrate limitation is a powerful therapeutic strategy to effectively, and safely, starve cancer cells to death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“However, tumor heterogeneity can limit the efficacy of these targeted agents [6–9].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 2×
“In summary, metabolic inhibitors suffer from the same limitations as therapies targeting oncogenic signal transduction cascades [10–13].”
BackgroundMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“As mentioned above, many excellent recent reviews describe how metabolic pathways are re-wired in cancer cells and the efforts to drug key enzymes in these pathways [1–5, 8, 19”
BackgroundCellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 3×
“How fatty acids enter cells is incompletely understood [119,121,122].”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Fasting: molecular mechanisms and clinical applications
Longo, V. D., & Mattson, M. P. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.008 · Cited by 1,425
Cited by
Li, S.-Y., Cheng, H., Xie, B.-R., Qiu, W.-X., Zeng, J.-Y., Li, C.-X., Wan, S.-S., Zhang, L., Liu, W.-L., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b02533 · Cited by 780
Kim, S. M., Nguyen, T. T., Ravi, A., Kubiniok, P., Finicle, B. T., Jayashankar, V., Malacrida, L., Hou, J., Robertson, J., Gao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1215 · Cited by 199
“4 INTRODUCTION Cancer cells up-regulate nutrient acquisition pathways to fuel oncogene-driven anabolism and proliferation (1).”
BackgroundMethodSelf-citationTargeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways
Kim, S. M., Roy, S. G., Chen, B., Nguyen, T. M., McMonigle, R. J., McCracken, A. N., Zhang, Y., Kofuji, S., Hou, J., Selwan, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87148 · Cited by 77
“As a single agent, SH-BC-893 acts like a combination therapy by targeting the multiple nutrient acquisition pathways that fuel cancer anabolism (17).”
BackgroundInfluentialSelf-citationHepowit, N. L., Moon, B., Ebert, A. C., Dickson, R. C., & MacGurn, J. A. (2023) · Journal of Cell Science · doi:10.1242/jcs.260675 · Cited by 18
Metadata
- Authors
- Selwan, E. M., Finicle, B. T., Kim, S. M., & Edinger, A. L.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2016-03-22
- Volume
- 590
- Issue
- 7
- Pages
- 885-907
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2292751194
- Cited by
- 69
- References
- 55
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attacking the supply wagons to starve cancer cells to death. https://app.cochat.ai/papers/10.1002/1873-3468.12121
- The paper
- Selwan, E. M., Finicle, B. T., Kim, S. M., & Edinger, A. L. (2016). Attacking the supply wagons to starve cancer cells to death. FEBS Letters. https://doi.org/10.1002/1873-3468.12121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.